SAB Biotherapeutics (SABS) EBIT Margin (2021 - 2025)
Historic EBIT Margin for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to 29287.09%.
- SAB Biotherapeutics' EBIT Margin changed N/A to 29287.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 69102.73%, marking a year-over-year increase of 725254000.0%. This contributed to the annual value of 3244.87% for FY2024, which is 15443200.0% down from last year.
- Per SAB Biotherapeutics' latest filing, its EBIT Margin stood at 29287.09% for Q3 2025.
- In the past 5 years, SAB Biotherapeutics' EBIT Margin registered a high of 29287.09% during Q3 2025, and its lowest value of 8726.26% during Q4 2024.
- Its 5-year average for EBIT Margin is 1654.83%, with a median of 160.26% in 2022.
- As far as peak fluctuations go, SAB Biotherapeutics' EBIT Margin tumbled by -74703700bps in 2023, and later surged by 190017700bps in 2025.
- SAB Biotherapeutics' EBIT Margin (Quarter) stood at 66.41% in 2021, then tumbled by -448bps to 363.74% in 2022, then plummeted by -1601bps to 6187.9% in 2023, then crashed by -41bps to 8726.26% in 2024, then soared by 436bps to 29287.09% in 2025.
- Its EBIT Margin was 29287.09% in Q3 2025, compared to 15124.81% in Q2 2025 and 15484.95% in Q1 2025.